Location, not staging, of XXXX determines the role for adjuvant chemoradiation therapy.

@entity1 @entity5 @entity1753 @entity2802 @entity201
The role of adjuvant chemoradiation therapy (CT/XRT) in the treatment of @entity201 is controversial. We undertook this study to determine whether CT/XRT is appropriate after resection of @entity201 . One hundred ninety-two @entity1 with @entity201 were treated from 1988 to 1999. After resection, @entity1 were assigned a stage ( @entity2802 ) and were stratified by location of the @entity5 as intrahepatic, perihilar, and @entity5 . Data are presented as mean +/- standard deviation. Of 192 @entity1 92 (48%) underwent resections of @entity201 . Thirty-four @entity1 had liver resections, 25 had bile duct resections, and 33 underwent pancreaticoduodenectomies. Thirty-four @entity1 had adjuvant CT/XRT, three had adjuvant chemotherapy, four had neoadjuvant CT/XRT, and 50 had no radiation or chemotherapy. Mean survival of resected @entity1 with adjuvant CT/XRT was 42 +/- 37.0 months and without CT/XRT it was 29 24.5 months (P = 0.07). Mean survival of @entity1 with @entity5 receiving or not receiving CT/XRT was 41 +/- 21.8 versus 25 +/- 20.1 months, respectively, (P = 0.04). @entity1753 improves survival after resection for @entity201 (P = 0.07) particularly in @entity1 undergoing resection for @entity5 (P = 0.04). Benefits of adjuvant CT/XRT are apparent when stratified by location of @entity201 rather than staging.
